Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-cell therapy plus checkpoint inhibitors in advanced ovarian and related cancers
2017-002179-24Phase 2Terminated
- Sponsor
- Center for Cancer Immune Therapy
- Start
- Jun 2017
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous tumor-infiltrating lymphocytes, nivolumab, ipilimumab, cyclophosphamide, fludarabine and 1 more in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Center for Cancer Immune Therapy. Primary endpoints: Primary toxicity endpoint and Feasibility endpoint. Started Jun 2017; status: terminated.
02
Drugs
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2017-002179-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002179-24.